Literature DB >> 17395030

Intraoperative management of hyperglycemia in the cardiac surgical patient.

Athos J Rassias1.   

Abstract

The stress response of cardiac surgery leads to hyperglycemia, and undergoing cardiopulmonary bypass magnifies this response greatly. Counter-regulatory hormones, the cytokine response, and the automatic nervous system are all part of the coordinated host response that can lead to hyperglycemia. Postoperative hyperglycemia is associated with worsened perioperative outcomes, and there are data demonstrating this to also be true for the intraoperative period. Many factors affect intraoperative glucose control, including cardiopulmonary pump (CPB) prime fluid composition, temperature while on CPB, and medications such as catecholamines and glucocorticoids. Intraoperative glucose control has a significant impact on postoperative outcomes. No optimal intraoperative insulin regimen has been identified, but continuous intravenous infusions appear to be superior to intermittent sliding scale dosing. In addition, the technique of hyperinsulinemic glucose clamp shows the greatest promise of achieving normoglycemia while on CPB.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17395030     DOI: 10.1053/j.semtcvs.2006.05.002

Source DB:  PubMed          Journal:  Semin Thorac Cardiovasc Surg        ISSN: 1043-0679


  2 in total

1.  Comparison of TIVA and Desflurane Added to a Subanaesthetic Dose of Propofol in Patients Undergoing Coronary Artery Bypass Surgery: Evaluation of Haemodynamic and Stress Hormone Changes.

Authors:  Didem Onk; Tülin Akarsu Ayazoğlu; Oruç Alper Onk; Mehmet Aksüt; Murat Günay; Kultigin Turkmen; Aynur Özensoy; Çiğdem Yazıcı Ersoy; Abdulkadir Çoban
Journal:  Biomed Res Int       Date:  2016-07-27       Impact factor: 3.411

2.  Evaluation of the effect of metformin and insulin in hyperglycemia treatment after coronary artery bypass surgery in nondiabetic patients.

Authors:  Kamran Ghods; Hossein Davari; Abbasali Ebrahimian
Journal:  Ann Card Anaesth       Date:  2017 Oct-Dec
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.